NCT03971162View on ClinicalTrials.gov

Intravitreal Conbercept Injection in Patients With Myopic Choroidal Neovascularization

NACompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

June 13, 2019

Primary Completion Date

December 1, 2022

Study Completion Date

January 1, 2023

Conditions
Myopic Choroidal Neovascularisation
Interventions
DRUG

3+PRN

intravitreal injection of Conbercept 0.5mg every month repeated for 3 months,

DRUG

6+PRN

intravitreal injection of Conbercept 0.5mg every month repeated for 6 months

Trial Locations (1)

510060

Zhongshan Ophthalmic Center, Guangzhou

All Listed Sponsors
lead

Zhongshan Ophthalmic Center, Sun Yat-sen University

OTHER

NCT03971162 - Intravitreal Conbercept Injection in Patients With Myopic Choroidal Neovascularization | Biotech Hunter | Biotech Hunter